Prostic Preceptorship 2022, happening the 1st and 2nd of April

Invited guest speakers

Dr. Arsha Anton

Arsha is a medical oncologist at Eastern Health with an interest in genitourinary and breast malignancies. After completing her undergraduate medical degree at the University of New South Wales, Arsha moved to Melbourne and underwent advanced training in Oncology through the Victorian Medical Oncology Training Program.

Arsha is also a clinical research fellow at the Walter and Eliza Hall Institute of Medical Research and is currently undertaking a higher research degree evaluating the use of clinical registries in optimising prostate cancer management. She is actively involved in clinical research and has presented at national and international conferences.

A/Prof. Arun Azad

A/Prof. Arun Azad is an internationally recognised medical oncologist and translational researcher in urological cancers, with a particular focus on prostate cancer.

After completing his medical training and a PhD at Peter Mac, he undertook a Fellowship in a world-renowned prostate cancer clinical and research program in Vancouver, under the supervision of Professor Kim Chi.

Dr. James Buteau

Dr Buteau completed his medical training in Canada with a specialization in nuclear medicine at the University of Sherbrooke. Following two years of practice among the dynamic team at Hôpital de la Cité-de-la-Santé, he undertook a 12-month fellowship in Theranostics at Peter Mac. In 2020, he was awarded with the Detweiler Travelling Fellowship by the Royal College of Physicians and Surgeons of Canada.

Prof. Jeff Dunn

Jeff Dunn is the Chief of Mission and Head of Research at the Prostate Cancer Foundation of Australia. Jeff is also Chair of Cancer Survivorship and Professor of Social and Behavioural Science at the University of Southern Queensland and is a Board Member and Chair of the Audit and Risk Committee for the West Moreton Hospital and Health Service. Having served on the Board of the Union for International Cancer Control in various capacities over many years, Jeff is the current President Elect and takes up the Presidency at the World Cancer Congress in October 2022. His work in cancer control spans 30 years, in which time he has dedicated his career to the development of strategies that underpin cancer survival and improve awareness of the disease with a special focus on the social and behavioural aspects of cancer and has over 200 publications, including peer reviewed manuscripts, chapters, books and reports. In 2014 Jeff was appointed an Officer in the Order of Australia for distinguished service to medical administration through leadership of cancer control organisations and promotion of innovative and integrated cancer care programmes.

Dr. Renu Eapen

Dr Renu Eapen is a Consultant Urologist in the Genitourinary Oncology service at the Peter MacCallum Cancer Centre. She also has appointments at the Austin Hospital and Olivia Newton-John Cancer Centre.

Dr. Matthias Eiber

Insert bio here.

Prof. Louise Emmett

Prof Louise Emmett is the Director of Theranostics and Nuclear
medicine at St Vincent’s Hospital Sydney, with a current specialty
interest in the imaging and therapy of prostate Cancer. She undertook
her medical undergraduate training in Auckland, New Zealand, prior to
completing her specialty training in Nuclear Medicine in Sydney, and a
post specialty Nuclear Cardiology fellowship in Toronto, Canada in 2001.
She has a strong interest in research completing a Doctorate of
Medicine in Nuclear Cardiology in 2012. She commenced work in Nuclear
medicine and PET at St Vincent’s Hospital, Sydney in 2012, initiating
radio-pharmacy production of multiple new imaging and therapy
peptides on the St Vincent’s campus for clinical and research evaluation.
She is heavily involved in multi-disciplinary prostate cancer research in Australia, including both imaging and therapy.

Prof. Wolfgang Fendler

Since 2018 Attending and Vice Chair of Nuclear Medicine at the Essen University Hospital; 2016-2017 Visiting Professor at the Department of Pharmacology at UCLA Los Angeles; 2011 to 2016: Resident at the LMU Munich University Hospital Nuclear Medicine

Dr. Heidi Fettke

Dr. Heidi Fettke is a postdoctoral scientist in the Translational Prostate Cancer Research Program at Peter Mac. Here she is working on identifying predictive and prognostic biomarkers in the blood of men with advanced prostate cancer in order to guide therapy selection and improve outcomes for these patients. 

A/Prof. Roslyn Francis

A/Prof Roslyn Francis is an academic Nuclear Medicine Physician. She is Head of Department at Sir Charles Gairdner Hospital Nuclear Medicine/WA PET Service and holds an academic role as Associate Professor of Molecular Imaging with University of Western Australia. Her research interests are focused on the role of imaging in clinical trials, quantitative imaging/analytics and investigating novel PET tracers.

Dr. Andrei Gafita

Dr. Andrei Gafita is a Postdoctoral Scholar in the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. His clinical research focuses on clinical optimization of a novel PSMA-targeted therapeutic agent for men with advanced prostate cancer. Besides that, he is working on developing mathematical models to predict clinical outcome and to use artificial intelligence algorithms for automatic detection of prostate cancer. His overarching goal is to clinically implement a patient-individualized approach for PSMA-targeted radioligand treatment and to evolve molecular PSMA-PET imaging as a quantitative imaging biomarker in prostate cancer. He is also currently a co-investigator of several ongoing clinical trials at UCLA that covers the field of PSMA theranostics.

Dr. Mohammad Haskali

Mohammad Haskali gained his Bachelor’s degree in analytical chemistry in 2008 from Victoria University (Australia). In 2014, Mohammad has submitted his PhD thesis from his research at the University of Melbourne in collaboration with the Peter MacCallum Cancer Centre.

Prof. Michael Hofman

Prof. Michael Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne.

He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in oncology. This includes neuroendocrine tumours and haematologic applications and more recently he has focussed on improving outcomes for men with prostate cancer.

Prof. Thomas Hope

Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is also the Associate Chair for Joint Ventures for Radiology. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013.

Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT program for neuroendocrine tumors and is developing the PSMA radioligand therapy program at UCSF.

A/Prof. George Hruby

A/Prof George Hruby is an academic radiation oncologist with advanced training, research and clinical specialty interest in both genito-urinary (prostate and bladder) and gastro-intestinal (oesophageal to anal) cancers. Following a general clinical fellowship at the Royal Prince Alfred Hospital in 1999, he was awarded an 18 month post-graduate fellowship at the University of Toronto specializing in GU malignancies and prostate brachytherapy. George has co-authored the radiation oncology section for the Cancer Council guidelines on managing rectal cancer and over the last 20 years has treated perhaps more anal cancer than any other radiation oncologist in Sydney due to his roles in the GI teams of both RNS and St Vincents hospitals (GenesisCare).

Dr. Price Jackson

Dr. Price Jackson is a diagnostic imaging medical physicist working with the Radiology and Nuclear Medicine departments at Peter MacCallum Cancer Centre. He has worked at the hospital since 2011 undertaking a mix of research and clinical work. Initially, this was in support of Peter Mac’s radionuclide therapy program for Neuroendocrine Cancer where he developed a number of computational tools to record radiation dose and estimate biological effect following treatment with Lutetium Octreotate. This has extended more recently into follow-up for Lu-PSMA therapy in prostate cancer where Price assists with several clinical trials coordinated through the ProsTIC Centre of Excellence.

Prof. Veeru Kasivisvanathan

Prof. Kasivisvanathan is an Academic Urologist with an interest in Prostate Cancer Imaging from University College London, currently working in the GU Oncology Unit at Peter MacCallum Cancer Centre. His work has contributed to the one of the most significant changes in how we diagnose prostate cancer for 30 years, promoting the use of multiparametric MRI upfront in men at suspicion of prostate cancer. He has published his landmark piece of work, the PRECISION trial, in the New England Journal of Medicine. He has been awarded a Hunterian Professorship from the Royal College of Surgeons of England, the John Anderson Award from the British Association of Urological Surgeons and the MDPI Medicina Young Investigator award for outstanding contribution to Urology.

A/Prof. Grace Kong

Grace Kong is a Nuclear Medicine Physician at the Peter MacCallum Cancer Centre (PMCC) in Melbourne Australia, a Clinical Associate Professor at the University of Melbourne, Sir Peter MacCallum Department of Oncology. She is the lead of the radionuclide therapy service, the chair of the neuroendocrine tumor (NET) multidisciplinary meeting (MDM) a European Neuroendocrine Tumor Society (ENETS) center of excellence, and nuclear medicine lead for the upper gastrointestinal tumor stream. She completed a fellowship in PET and radionuclide therapy at the Royal Marsden Hospital UK. She is a recipient of the Foundation Discovery Partner Fellowship grant award. She has broad clinical and research interests in cancer imaging, radionuclide therapy, with a focus in advancing theranostics for endocrine, NET and prostate cancer. She has published multiple peer-reviewed journals, leads several national and international collaborative clinical trials. She participates in research and education at national and international meetings and is a reviewer for several oncology and imaging journals.

Dr. Louise Kostos

Dr. Louise Kostos is a Medical Oncologist and PhD candidate. She obtained her medical degree with honours from Monash University in 2013 and completed her advanced training in Medical Oncology in Melbourne in 2020. She has an interest in phase 1 trial design and genitourinary cancers. Louise is currently undertaking a PhD under the supervision of Prof Michael Hofman and A/Prof Arun Azad. Her PhD focuses on optimising outcomes for men with metastatic castration resistant prostate cancer treated with PSMA-based radionuclide therapy.

Dr. Aravind Ravi Kumar

Dr. Aravind S. Ravi Kumar is a nuclear medicine physician at the Peter MacCallum Cancer Centre. Aravind was awarded his medical degree from Sydney University in 1995 and his FRACP in Nuclear Medicine in 2003 via a detour in clinical haematology. He worked at the Royal Brisbane and Women’s Hospital for 12 years before moving to the Peter MacCallum Cancer Centre in 2016. He is an active member of multi-disciplinary teams and has a strong interest in theranostics and enjoys opportunities for integrating clinical and technical aspects of practice. He is currently involved in clinical care and research in prostate, neuroendocrine and thyroid cancers, and has had multiple other roles in governance, education and training from local to national levels throughout his career.

Dr. Su-Faye Lee

Dr. Su-Faye Lee is a dual trained Radiologist/Nuclear Medicine Specialist at Peter MacCallum Cancer Centre, who also has appointments at Western Health. She undertook her medical degree at UNSW, Sydney and went on to complete her Radiology and Nuclear Medicine training at St Vincent’s Hospital, Melbourne and Royal Melbourne Hospital. She has an interest in prostate imaging, having recently taken part in a hybrid MRI/PSMA PET imaging trial at St Vincent’s.

A/Prof. Sze-Ting Lee

Associate Professor Sze Ting Lee is a Nuclear Medicine Physician at the Department of Molecular Imaging and Therapy at Austin Health, Melbourne.

She is the Deputy Director and Director of Training, the PET Lead in Lymphoma and Theranostics Trials in the department. Her clinical and research interests lie in the novel tracers and applications of Molecular Imaging and Therapy in Oncological diseases, from phase 1 antibody trials through to participating in multicentre phase 3 clinical trials in this space.

She is also the current Vice President of the Australasian Association of Nuclear Medicine Specialists (AANMS), Past President of the ANZSNM, and the immediate past Secretary General of the World Federation of Nuclear Medicine and Biology (WFNMB). She is currently Vice-President of the Asia-Oceania Federation of Nuclear Medicine and Biology (AOFNMB), and Governing Board Member of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). She is the recently nominated Lead on the Minimum Requirement for Theranostics for the IAEA/Lancet Oncology Commission in Theranostics.

Dr. Genevieve Loos

Dr Loos is a Radiation Oncologist in France at the UNICANCER National Comprehensive Cancer
Institute, at Clermont Ferrand, which is recognised as one of the leading cancer treatment centres in France.
At Clermont Ferrand, Dr Loos is responsible for the treatment of Urological and Gynaecological cancer and
has recently implemented HDR brachytherapy in Prostate Cancer in her Centre. Dr Loos also experience with
68Ga-PSMA-11 PET/CT at her centre (one of the first centres in France with this imaging technique) . Dr Loos is an active clinical trialist is a member
of the French National urological cancer group (GETUG)

Elizabeth Medhurst

Elizabeth Medhurst has been a Genitourinary nurse consultant for the past four years. Elizabeth has developed a keen interest in metastatic prostate cancer and is passionate about participating in prostate cancer research and highlighting the importance of the nursing role throughout the process. 

Lachlan McIntosh

Lachlan McIntosh is a PhD candidate currently also in training as a diagnostic imaging medical physicist at the Peter MacCallum Cancer Centre. His main interests are in theranostics and deep learning. His PhD thesis aims to develop artificial intelligence-based software capable of assisting clinical decisions for LuPSMA therapy.

A/Prof. Daniel Moon

A/Prof Daniel Moon is a Urologist with subspecialty expertise in prostate cancer diagnosis and management.  He served as the inaugural Director of Robotic Surgery at Epworth Healthcare 2012-2017 and is an Honorary Clinical Associate Professor at The University of Melbourne. He has performed over 2000 major laparoscopic and robotic procedures, published the first Australian series of laparoscopic radical prostatectomy in 2008, performed the first Australian robotic cysto-prostatectomy in 2009, and established a robotic partial nephrectomy program at Peter MacCallum Cancer Centre, publishing the first Australian series of this procedure in 2014 and the largest Australian partial nephrectomy series in 2017. A/Prof Moon has developed comprehensive training and credentialing documents for surgeons learning robotics, has received European Association of Urology certification as a trainer in robotic surgery and is on the Editorial Board of the British Journal of Urology International.

Prof. Declan Murphy

Professor Declan Murphy is Consultant Urologist and Director of Genito-Urinary (GU) Oncology at Peter MacCallum Cancer Centre, Melbourne, and Professorial Fellow at the University of Melbourne. He is a founding Director of Cancer Specialists.

Ms. Sally Sara

Sally Sara knows first-hand the difference that a Prostate Cancer Specialist Nurse can make in the life of men and their families having established the role in Southern Adelaide in 2014. In 2018 Sally took on the role of Director Nursing Programs, Prostate Cancer Foundation of Australia, which made her responsible for oversight and development of the service nationally. Sally is passionate that more men and their families have access to this life-changing support as they face prostate cancer. Although her new role does not directly involve clinical work, Sally continues to be personally inspired and driven by the stories of the families that she encountered and supported in her role in Adelaide.  

Sally said, “It was my absolute privilege to be a Prostate Cancer Specialist Nurse – across a career spanning 30 years it was by far the most rewarding role I had undertaken. However, I am excited by the potential these Prostate Cancer Specialist Nursing roles hold for the future and am delighted to now be responsible for overseeing and further developing the service nationally.”

"Our nurses are there when a man receives the news that they have been diagnosed with prostate cancer – which can be one of the most difficult times in their lives. It’s a very challenging time also because prostate cancer often comes with a range of potential treatment options, so it can be challenging to make that choice. Our nurses are also involved in helping men and their families emotionally and psychologically. They also play an important role in side-effect management following treatment which can be quite debilitating."

"In far too many cases, men with prostate cancer live with long-lasting impacts on physical and psychological wellbeing and often find it difficult to seek or find help or support. From the moment that a man is diagnosed, their Prostate Cancer Specialist Nurse becomes the main point of contact for any issues or concern the men and their families may have, including management of symptoms and treatment side effects – there is no end-point to this care."

"Patients often tell us that they need "an opportunity to talk through [their] diagnosis beyond what is available in a standard 15-minute consult with a urologist". A Prostate Cancer Specialist Nurse can help patients and their families to understand their diagnosis, what to expect and connect them with services to address the challenges that they may encounter along the way."

“Prostate cancer is too frightening to face alone. Our nurses are there to support men at one of the most difficult times in their lives, to help them understand their diagnosis, the treatment options available to them and also to coordinate their care so that they get all of the help that they need.” 

“We know that this expert support from a Prostate Cancer Specialist Nurse can be life-changing for men and their families who are dealing with prostate cancer. From the moment that these men are diagnosed, the prostate cancer specialist nurse can become their main point of contact to discuss any issues that they may have in relation to their diagnosis, treatment, side effect management and after care.”

A/Prof. Shahneen Sandhu

A/Prof. Sandhu is a Medical Oncologist and an early-career researcher and with a full time appointment in uro-oncology and melanoma units at the Peter MacCallum Centre, Melbourne. She trained at the Royal Marsden NHS Foundation Trusts/Institute of Cancer Research Drug Development Unit, and was responsible for designing, implementing and supervising early phase adaptive, biomarker driven trials. Over the course of her research career, A/Professor Sandhu has made important original contributions to cancer research, particularly in the development and application of clinical biomarkers. She continues to undertake clinical and translational research in immune-oncology in melanoma and prostate cancer with a focus on using imaging and circulating biomarkers to molecularly stratify treatment.

Mark Scalzo

Mark Scalzo studied Medical Radiation Sciences at RMIT University, and on completion of his degree started work at King’s College Hospital (KCH) NHS Foundation Trust in South East London in December 1999. After 5 years at KCH, under the mentorship of Dr. Muriel Buxton-Thomas, Mark returned to Melbourne with his family, and started work at Peter MacCallum Cancer Centre in November 2004. His time as a Nuclear Medicine Technologist (NMT) in London produced a desire to concentrate on Nuclear Theranostics.

A/Prof. Shankar Siva

Associate Professor Shankar Siva is a Radiation Oncologist and current Cancer Council Victoria (CCV) Colebatch Fellow. He leads the Stereotactic Ablative Body Radiotherapy (SABR) program at the Peter Mac and is internationally recognised for his work in high technology radiotherapy delivery. He completed his PhD with the Molecular Radiation Biology (Martin) Laboratory focusing on translational investigations in precision high-dose lung radiotherapy. He published the first original research from Australia on the use of the SABR technique.

Prof. Silke Gillessen Sommer

Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer.

 

She completed her training in Basel, St. Gallen, and the Dana Farber Cancer Institute, Boston. After returning to Switzerland, she built up the medical oncology unit for genitourinary cancer and headed the clinical research unit for oncology/haematology in Cantonal Hospital, St Gallen.
She served for two terms as president of the SAKK GU group, she chaired the EORTC Genitourinary Cancers Group, and has founded the Advanced Prostate Cancer Consensus Conference (APCCC).

 

Since 2018, Prof Gillessen has been Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester and Honorary Consultant at The Christie Hospital, while continuing to work as Consultant in the Department of Oncology/Haematology at the Kantonsspital St. Gallen, Switzerland.

 

In January 2020 Prof Gillessen was appointed Head of the Department of Medical Oncology, full professor at the Università della Svizzera Italiana (USI) in Lugano and Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona, Switzerland

Prof. Scott Williams

Professor Scott Williams is a radiation oncologist who works exclusively with urological cancers, and in particular, prostate cancer. He is Professor of Oncology at University of Melbourne and Honorary Professor of Medicine at University of Queensland. Scott has an international profile as the lead of several large global studies of hormonal therapy combined with radiotherapy in prostate cancer, while also managing multiple smaller studies locally and nationally. His research largely focuses on how prostate cancer responds to radiation therapy (in particular related to brachytherapy), including recent molecular and immune system insights derived from extensive laboratory investigations. Other avenues of work involve global collaborations to evaluate outcomes measures used in clinical trials, along with a large body of work evaluating novel imaging and targeted radio-isotope therapy in prostate cancer.

A/Prof. Shankar Siva

Associate Professor Shankar Siva is a Radiation Oncologist and current Cancer Council Victoria (CCV) Colebatch Fellow. He leads the Stereotactic Ablative Body Radiotherapy (SABR) program at the Peter Mac and is internationally recognised for his work in high technology radiotherapy delivery. He completed his PhD with the Molecular Radiation Biology (Martin) Laboratory focusing on translational investigations in precision high-dose lung radiotherapy. He published the first original research from Australia on the use of the SABR technique.

Prof. Silke Gillessen Sommer

Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer.

 

She completed her training in Basel, St. Gallen, and the Dana Farber Cancer Institute, Boston. After returning to Switzerland, she built up the medical oncology unit for genitourinary cancer and headed the clinical research unit for oncology/haematology in Cantonal Hospital, St Gallen.
She served for two terms as president of the SAKK GU group, she chaired the EORTC Genitourinary Cancers Group, and has founded the Advanced Prostate Cancer Consensus Conference (APCCC).

 

Since 2018, Prof Gillessen has been Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester and Honorary Consultant at The Christie Hospital, while continuing to work as Consultant in the Department of Oncology/Haematology at the Kantonsspital St. Gallen, Switzerland.

 

In January 2020 Prof Gillessen was appointed Head of the Department of Medical Oncology, full professor at the Università della Svizzera Italiana (USI) in Lugano and Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona, Switzerland

Prof. Scott Williams

Professor Scott Williams is a radiation oncologist who works exclusively with urological cancers, and in particular, prostate cancer. He is Professor of Oncology at University of Melbourne and Honorary Professor of Medicine at University of Queensland. Scott has an international profile as the lead of several large global studies of hormonal therapy combined with radiotherapy in prostate cancer, while also managing multiple smaller studies locally and nationally. His research largely focuses on how prostate cancer responds to radiation therapy (in particular related to brachytherapy), including recent molecular and immune system insights derived from extensive laboratory investigations. Other avenues of work involve global collaborations to evaluate outcomes measures used in clinical trials, along with a large body of work evaluating novel imaging and targeted radio-isotope therapy in prostate cancer.